Application 091049
- Type
- ANDA
- Sponsor
- ASTRAL
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | CEFTRIAXONE | CEFTRIAXONE SODIUM | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | EQ 250MG BASE/VIAL | No | No |
| 002 | CEFTRIAXONE | CEFTRIAXONE SODIUM | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | EQ 500MG BASE/VIAL | No | No |
| 003 | CEFTRIAXONE | CEFTRIAXONE SODIUM | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | EQ 1GM BASE/VIAL | No | No |
| 004 | CEFTRIAXONE | CEFTRIAXONE SODIUM | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | EQ 2GM BASE/VIAL | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A091049-001 | CEFTRIAXONE | CEFTRIAXONE SODIUM | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | ||
| A091049-002 | CEFTRIAXONE | CEFTRIAXONE SODIUM | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | ||
| A091049-003 | CEFTRIAXONE | CEFTRIAXONE SODIUM | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | ||
| A091049-004 | CEFTRIAXONE | CEFTRIAXONE SODIUM | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A091049-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | A091049-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | A091049-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | A091049-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A091049-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | A091049-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | A091049-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | A091049-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A091049-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A091049-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A091049-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A091049-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A091049-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A091049-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A091049-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A091049-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A091049-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A091049-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A091049-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A091049-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A091049-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A091049-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A091049-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A091049-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A091049-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A091049-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A091049-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A091049-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A091049-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A091049-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A091049-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A091049-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A091049-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A091049-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A091049-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A091049-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A091049-001 | CEFTRIAXONE | EQ 250MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A091049-002 | CEFTRIAXONE | EQ 500MG BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A091049-003 | CEFTRIAXONE | EQ 1GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A091049-004 | CEFTRIAXONE | EQ 2GM BASE/VIAL | INJECTABLE / INTRAMUSCULAR, INTRAVENOUS | 2018-06-11 | 5bbf6a4d5a75… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A091049-001 | AP | 1 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A091049-002 | AP | 1 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A091049-003 | AP | 1 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A091049-004 | AP | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A091049-001 | AP | 1 | 5d02ea3f76ae… |
| 2022-04-08 23:34 UTC | 2022-04 | A091049-002 | AP | 1 | 5d02ea3f76ae… |
| 2022-04-08 23:34 UTC | 2022-04 | A091049-003 | AP | 1 | 5d02ea3f76ae… |
| 2022-04-08 23:34 UTC | 2022-04 | A091049-004 | AP | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A091049-001 | AP | 1 | 4b0b4de00fa7… |
| 2022-04-04 05:41 UTC | 2022-04 | A091049-002 | AP | 1 | 4b0b4de00fa7… |
| 2022-04-04 05:41 UTC | 2022-04 | A091049-003 | AP | 1 | 4b0b4de00fa7… |
| 2022-04-04 05:41 UTC | 2022-04 | A091049-004 | AP | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A091049-001 | AP | 1 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | A091049-002 | AP | 1 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | A091049-003 | AP | 1 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | A091049-004 | AP | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A091049-001 | AP | 1 | bb7c543d1eb4… |
| 2022-03-09 01:35 UTC | 2022-03 | A091049-002 | AP | 1 | bb7c543d1eb4… |
| 2022-03-09 01:35 UTC | 2022-03 | A091049-003 | AP | 1 | bb7c543d1eb4… |
| 2022-03-09 01:35 UTC | 2022-03 | A091049-004 | AP | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A091049-001 | AP | 1 | 782e0a99824c… |
| 2021-12-28 21:50 UTC | 2021-12 | A091049-002 | AP | 1 | 782e0a99824c… |
| 2021-12-28 21:50 UTC | 2021-12 | A091049-003 | AP | 1 | 782e0a99824c… |
| 2021-12-28 21:50 UTC | 2021-12 | A091049-004 | AP | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A091049-001 | AP | 1 | 87673890dc5c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A091049-002 | AP | 1 | 87673890dc5c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A091049-003 | AP | 1 | 87673890dc5c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A091049-004 | AP | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A091049-001 | AP | 1 | 5aa47cf7b7d7… |
| 2021-03-12 10:30 UTC | 2021-03 | A091049-002 | AP | 1 | 5aa47cf7b7d7… |
| 2021-03-12 10:30 UTC | 2021-03 | A091049-003 | AP | 1 | 5aa47cf7b7d7… |
| 2021-03-12 10:30 UTC | 2021-03 | A091049-004 | AP | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A091049-001 | AP | 1 | 8869cabd3fbd… |
| 2020-12-22 03:56 UTC | 2020-12 | A091049-002 | AP | 1 | 8869cabd3fbd… |
| 2020-12-22 03:56 UTC | 2020-12 | A091049-003 | AP | 1 | 8869cabd3fbd… |
| 2020-12-22 03:56 UTC | 2020-12 | A091049-004 | AP | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A091049-001 | AP | 1 | c0c555d07b60… |
| 2020-11-12 02:37 UTC | 2020-11 | A091049-002 | AP | 1 | c0c555d07b60… |
| 2020-11-12 02:37 UTC | 2020-11 | A091049-003 | AP | 1 | c0c555d07b60… |
| 2020-11-12 02:37 UTC | 2020-11 | A091049-004 | AP | 1 | c0c555d07b60… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | A-S Medication Solutions | 1aa0a4ee-1b39-4c3d-a7a3-33dded6fe28c | 2024-01-31 | Warnings, Adverse reactions | CEFTRIAXONE SODIUM |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | A-S Medication Solutions | ff8e830a-c288-46fb-9e19-ec2017943c07 | 2024-01-31 | Warnings, Adverse reactions | CEFTRIAXONE SODIUM |
| ceftriaxone | CEFTRIAXONE | Sagent Pharmaceuticals | 5cf93bc5-9e4c-4734-bc02-c7d0ac071022 | 2023-11-08 | Warnings, Adverse reactions | ceftriaxone |
| Ceftriaxone | CEFTRIAXONE | Fresenius Kabi USA, LLC | 7ea1db43-40fa-417b-8911-ae98092070a0 | 2023-09-30 | Warnings, Adverse reactions | Ceftriaxone |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Asclemed USA, Inc. | f01cf0e5-caaf-4759-ba21-50f3aceff523 | 2023-09-02 | Warnings, Adverse reactions | CEFTRIAXONE SODIUM |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Apotex Corp. | 5116231f-82d1-44be-b08e-560c9a50e5c5 | 2023-08-31 | Warnings, Adverse reactions | CEFTRIAXONE SODIUM |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Apotex Corp. | ac03a72c-0e35-40f9-b7fc-081badb5f19c | 2023-01-28 | Warnings, Adverse reactions | CEFTRIAXONE SODIUM |
| Ceftriaxone | CEFTRIAXONE SODIUM | Samson Medical Technologies, LLC | 5cd2d96f-83e5-4326-ae87-d0ede4ba493a | 2023-01-15 | Warnings, Adverse reactions | Ceftriaxone CEFTRIAXONE SODIUM |
| Ceftriaxone | CEFTRIAXONE | Proficient Rx LP | fcf401df-bcdc-4773-a63b-9741c0f74b3d | 2022-11-01 | Warnings, Adverse reactions | Ceftriaxone |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Proficient Rx LP | a25ab5ea-c46d-4562-8f7e-0ccffc2ab069 | 2022-10-01 | Warnings, Adverse reactions | CEFTRIAXONE SODIUM |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Proficient Rx LP | 42ba7a9d-7d2b-4eac-af59-897151a8c924 | 2022-05-02 | Warnings, Adverse reactions | CEFTRIAXONE SODIUM |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Hospira, Inc | 9d1f630b-e759-4395-9d01-ddc90e4fea75 | 2022-03-09 | Warnings, Adverse reactions | CEFTRIAXONE SODIUM |
| Ceftriaxone | CEFTRIAXONE | Hikma Pharmaceuticals USA Inc. | 8351aa37-552d-471d-b293-c564dcb6ec29 | 2021-12-01 | Warnings, Adverse reactions | Ceftriaxone |
| Ceftriaxone | CEFTRIAXONE | Hikma Pharmaceuticals USA Inc. | 1f8776bd-4f5b-427a-849a-6b8338f7997d | 2019-04-24 | Warnings, Adverse reactions | Ceftriaxone |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 66794-211 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-211 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-211 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-211 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-211 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-211 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-212 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-212 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-212 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-212 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-212 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-212 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-213 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-213 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-213 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-213 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-213 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-213 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-214 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-214 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-214 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-214 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-214 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 66794-214 | Ceftriaxone | Ceftriaxone | Piramal Critical Care Inc | ANDA | Current |
| 70594-094 | Ceftriaxone | Ceftriaxone | Xellia Pharmaceuticals USA LLC | ANDA | Current |
| 70594-095 | Ceftriaxone | Ceftriaxone | Xellia Pharmaceuticals USA LLC | ANDA | Current |
| 70594-096 | Ceftriaxone | Ceftriaxone | Xellia Pharmaceuticals USA LLC | ANDA | Current |
| 70594-097 | Ceftriaxone | Ceftriaxone | Xellia Pharmaceuticals USA LLC | ANDA | Current |